How Much Does a Generic Save? A Data Analysis Across 26 Drug Classes

Generic drugs save Americans an estimated $400 billion per year — but the savings are not evenly distributed. A patient switching from brand-name Lipitor to generic atorvastatin saves roughly $200 per month. A patient taking Eliquis has no generic to switch to. And a patient on Ozempic faces a monthly list price of $936 with no generic alternative in sight.

This original analysis examines pricing data across all 26 drug classes in the RxGuide database to answer a deceptively simple question: how much does a generic actually save, and which drug classes offer the greatest opportunity for cost reduction?

Methodology

This analysis uses pricing data from the RxGuide drug database, which covers 284 drugs across 26 therapeutic classes. Typical monthly cost ranges are sourced from NADAC (National Average Drug Acquisition Cost) data published by CMS, supplemented by GoodRx pricing data and manufacturer list prices. Generic savings are calculated as the percentage reduction from brand-name list price to the lowest available generic price. Drug classes are classified as "no generic available" when no FDA-approved generic equivalent exists for any drug in the class.

The analysis is consistent with findings from the HHS/ASPE report Drug Competition Series: Analysis of New Generic Markets (January 2025), which found that generic prices decline by 70–80% relative to pre-generic entry prices in markets with 10 or more competitors.

Generic Availability by Drug Class

Source: RxGuide drug database. Generic availability as of March 2026. Savings percentages are approximate averages across drugs in each class.

The Classes With No Generic Options: A $50 Billion Problem

Three drug classes in this analysis have zero generic alternatives: GLP-1 receptor agonists, SGLT2 inhibitors, and direct oral anticoagulants (DOACs like Eliquis and Xarelto). Together, these three classes account for an estimated $50+ billion in annual Medicare Part D spending alone.

GLP-1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are all still under patent protection. The earliest generic semaglutide could enter the market is the late 2020s, pending patent litigation. Until then, patients face monthly costs of $900–$1,350 with no generic alternative.

SGLT2 Inhibitors (Jardiance, Farxiga, Invokana) are similarly patent-protected. These drugs have demonstrated significant cardiovascular and kidney-protective benefits beyond glucose control, making them increasingly important in diabetes and heart failure management — but at $400–$600 per month without insurance.

Direct Oral Anticoagulants (Eliquis, Xarelto, Pradaxa) represent perhaps the most acute affordability problem. These drugs have largely replaced warfarin (a generic that costs $4–$10/month) for stroke prevention in atrial fibrillation. The clinical advantages of DOACs over warfarin are real but modest for many patients, yet the price difference is enormous: $500–$600/month versus $4–$10/month.

The Classes With the Greatest Generic Savings

At the other end of the spectrum, several drug classes offer near-universal generic availability with dramatic cost savings:

Loop Diuretics offer the highest average generic savings in this analysis — approximately 92%. Furosemide (generic Lasix) costs $4–$10/month as a generic, compared to $80–$120/month for brand-name formulations. This class is widely used for heart failure and edema management.

Biguanides (Metformin) offer approximately 94% savings — the highest of any class. Generic metformin costs $4–$15/month at most pharmacies, making it one of the most cost-effective medications in existence. It remains the first-line treatment for type 2 diabetes in most clinical guidelines.

Beta-Blockers offer approximately 90% savings, with generic metoprolol and atenolol available for $4–$15/month. These drugs are used for hypertension, heart failure, and arrhythmia management.

Benzodiazepines offer approximately 91% savings, though this class carries significant addiction risk and is generally not recommended for long-term use.

The DPP-4 Inhibitor Exception: A Cautionary Tale

DPP-4 inhibitors (sitagliptin/Januvia, saxagliptin/Onglyza, alogliptin/Nesina) present an interesting case study. The class has 40% generic availability — Januvia's patent expired in 2022, and generic sitagliptin entered the market in 2023. However, the generic savings are only approximately 35%, far below the 80–90% savings seen in older drug classes.

This reflects a well-documented pattern in pharmaceutical economics: generic savings are smaller and slower to materialize for drugs that entered the market more recently, where fewer generic manufacturers have entered the market. According to the HHS/ASPE analysis, generic prices decline by 70–80% relative to brand-name prices only in markets with 10 or more generic competitors — a threshold that newly genericized drugs often take several years to reach.

What This Means for Patients

For patients taking medications in classes with robust generic availability, the message is clear: ask your doctor or pharmacist whether a generic equivalent is available. The savings can be substantial — often $100–$300 per month for commonly prescribed medications.

For patients taking medications in classes with no generic alternatives (GLP-1s, SGLT2 inhibitors, DOACs), the options are more limited:

Manufacturer savings programs. Most brand-name drug manufacturers offer savings cards or patient assistance programs. Novo Nordisk's savings card for Ozempic can reduce out-of-pocket costs to $25/month for commercially insured patients. However, these programs do not apply to Medicare or Medicaid beneficiaries.

Therapeutic substitution. In some cases, a patient taking a brand-name drug with no generic may be able to switch to a different drug in the same class that does have a generic. For example, a patient on Eliquis (no generic) might discuss with their physician whether warfarin (generic, $4–$10/month) is appropriate for their specific situation.

Patient assistance programs. Most major pharmaceutical manufacturers offer free or reduced-cost medications for patients who meet income eligibility requirements. The RxGuide drug pages include patient assistance program information for each drug.

Limitations

Generic savings percentages in this analysis are approximate averages across drugs in each class and should not be used as precise cost estimates for individual medications. Actual savings vary based on specific drug, dosage, pharmacy, insurance coverage, and geographic location. The analysis uses list prices as the baseline for brand-name drugs; actual prices paid by insurers and pharmacy benefit managers after rebates are lower and not publicly disclosed.

References

1. HHS/ASPE. Drug Competition Series: Analysis of New Generic Markets. aspe.hhs.gov. January 2025. https://aspe.hhs.gov/sites/default/files/documents/510e964dc7b7f00763a7f8a1dbc5ae7b/aspe-ib-generic-drugs-competition.pdf

2. FDA. Generic Competition and Drug Prices. fda.gov. November 2025. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices

3. Centers for Medicare & Medicaid Services. NADAC (National Average Drug Acquisition Cost). medicaid.gov. https://www.medicaid.gov/medicaid/nadac

4. Centers for Medicare & Medicaid Services. Medicare Part D Spending by Drug, 2023. data.cms.gov. https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug

5. Tsipas S, et al. Spending on Glucagon-Like Peptide-1 Receptor Agonists in the US, 2018–2023. JAMA Network Open. 2025. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832114

6. Association for Accessible Medicines. Generic Drug & Biosimilar Access & Savings in the U.S. accessiblemeds.org. https://accessiblemeds.org/resources/reports/generic-drug-biosimilar-access-savings-us

This article was reviewed by the RxGuide Editorial Team. Pricing data is sourced from CMS NADAC, GoodRx, and manufacturer list prices. This content is for informational purposes only and does not constitute medical or financial advice.